Product Description
Belatacept is a selective costimulation blocker that has been developed to improve long-term outcomes in kidney-transplant recipients by providing effective immunosuppression without the toxic effects of calcineurin inhibitors. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1506027)
Mechanisms of Action: Calcineurin Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Colombia | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Russia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: Kidney Transplant | Transplantation Unspecified
Known Adverse Events: Hypertension | Headache | Anemia | Leukopenia | Hyperkalemia | Hypokalemia | Constipation | Diarrhea | Edema
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Transplant|Renal Transplant
Phase 2: Arthritis, Rheumatoid|Heart Transplant|Lung Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IM103402 | P3 |
Unknown Status |
Renal Transplant |
2028-03-13 |
|
| 2018-000237-12 | P3 |
Active, not recruiting |
Renal Transplant |
2027-09-18 |
|
| ATTAIN | P2 |
Recruiting |
Kidney Transplant |
2027-03-31 |
|
| ADAPT | P2 |
Recruiting |
Kidney Transplant |
2027-02-28 |